Adults 18 to 40, any sex, with Obesity or Life Style. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Primary OutcomePrimary· 3 months
Turkish version of the Impact of Weight on Quality of Life-Lite Version (IWQOL) scale was used. The scale has a minimum score of 0 and a maximum of 100. The scoring system is valid for both the scale subgroups and the scale total score. Based on the scale scoring, quality-of-life decreases as the score decreases.
Physical function (baseline)
Group
Value
95% CI
Intervention Group
68.18
0 – 93.18
Control-1 Group
68.18
4.55 – 97.73
Control-2 Group
70.45
9.09 – 100
Self-esteem (baseline)
Group
Value
95% CI
Intervention Group
50
0 – 100
Control-1 Group
57.14
0 – 96.43
Control-2 Group
50
0 – 100
Sexual life (baseline)
Group
Value
95% CI
Intervention Group
75
0 – 100
Control-1 Group
87.50
0 – 100
Control-2 Group
81.25
0 – 100
Public distress (baseline)
Group
Value
95% CI
Intervention Group
90
15 – 100
Control-1 Group
85
10 – 100
Control-2 Group
85
0 – 100
Work (baseline)
Group
Value
95% CI
Intervention Group
75
0 – 100
Control-1 Group
87.50
0 – 100
Control-2 Group
87.50
0 – 100
Total Score (baseline)
Group
Value
95% CI
Intervention Group
63.79
16.38 – 95.69
Control-1 Group
73.28
28.45 – 93.97
Control-2 Group
69.83
18.97 – 99.14
Physical function (3 months)
Group
Value
95% CI
Intervention Group
79.54
0 – 100
Control-1 Group
77.27
22.73 – 100
Control-2 Group
84.09
0 – 100
Self-esteem (3 months)
Group
Value
95% CI
Intervention Group
75
0 – 100
Control-1 Group
82.14
0 – 100
Control-2 Group
60.71
3.57 – 100
SecondarySecondary· 3 months
Comparing the anthropometric measurements of the three groups at baseline and week 12.
Weight (kg) (Baseline)
Group
Value
95% CI
Intervention Group
89.50
66.10 – 125.80
Control-1 Group
84.50
61.90 – 135
Control-2 Group
85.10
64.20 – 108.40
Fat mass (kg) (Baseline)
Group
Value
95% CI
Intervention Group
33.50
13 – 63.60
Control-1 Group
28.70
17.20 – 48.80
Control-2 Group
26.80
11.30 – 51.50
Fat free mass (kg) (Baseline)
Group
Value
95% CI
Intervention Group
52.80
43.10 – 83.30
Control-1 Group
50
41.70 – 89.20
Control-2 Group
53.40
40.70 – 78.60
Weight (kg) (3 months)
Group
Value
95% CI
Intervention Group
88
65.60 – 128.60
Control-1 Group
79.90
58.80 – 135
Control-2 Group
84
62.30 – 108.40
Fat mass (kg) (3 months)
Group
Value
95% CI
Intervention Group
31.10
13 – 64.20
Control-1 Group
28.80
11.40 – 47.50
Control-2 Group
25.20
5 – 51.50
Fat free mass (kg)(3 months)
Group
Value
95% CI
Intervention Group
51.90
43.40 – 82
Control-1 Group
48.50
37.10 – 89.20
Control-2 Group
53.80
41.90 – 75.30
BMI (kg/m2)Secondary· 3 months
Comparing the BMI of the three groups at baseline and week 12.
BMI (kg/m2) (Baseline)
Group
Value
95% CI
Intervention Group
31.50
25 – 47.30
Control-1 Group
30.50
25.30 – 43.20
Control-2 Group
29.70
25 – 42.30
BMI (kg/m2) (3 months)
Group
Value
95% CI
Intervention Group
30.60
24.30 – 48.40
Control-1 Group
29.50
23 – 42.80
Control-2 Group
29.20
24.80 – 42.30
Waist Circumference (cm)Secondary· 3 months
Comparing the Waist Circumference measurements of the three groups at baseline and week 12.
Waist circumference (cm) (Baseline)
Group
Value
95% CI
Intervention Group
106
85.50 – 140
Control-1 Group
101.50
77 – 158
Control-2 Group
101
86 – 132
Waist circumference (cm) (3 months)
Group
Value
95% CI
Intervention Group
102
80 – 141
Control-1 Group
100
70 – 158
Control-2 Group
100
80.80 – 132
Lipid ProfileSecondary· 3 months
Lipid profile of the three groups at baseline and week 12.
Triglyceride (Baseline)
Group
Value
95% CI
Intervention Group
105
35 – 375
Control-1 Group
110
39 – 231
Control-2 Group
94
50 – 335
Total cholesterol (Baseline)
Group
Value
95% CI
Intervention Group
188
141 – 266
Control-1 Group
193
131 – 284
Control-2 Group
181
99 – 315
LDL cholesterol (Baseline)
Group
Value
95% CI
Intervention Group
121
68 – 180
Control-1 Group
120
71 – 181
Control-2 Group
126
74 – 231
HDL cholesterol (Baseline)
Group
Value
95% CI
Intervention Group
45
30 – 84
Control-1 Group
50
31 – 90
Control-2 Group
46
28 – 69
Triglyceride (3 months)
Group
Value
95% CI
Intervention Group
100
36 – 503
Control-1 Group
98
45 – 230
Control-2 Group
96
49 – 657
Total cholesterol (3 months)
Group
Value
95% CI
Intervention Group
189
120 – 282
Control-1 Group
189
111 – 256
Control-2 Group
173
105 – 324
LDL cholesterol (3 months)
Group
Value
95% CI
Intervention Group
128
70 – 193
Control-1 Group
125
81 – 174
Control-2 Group
129
88 – 258
HDL cholesterol (3 months)
Group
Value
95% CI
Intervention Group
50
33 – 87
Control-1 Group
48
31 – 88
Control-2 Group
48
27 – 67
Sponsor's own description
The goal of this clinical trial is to compare in the effect of different lifestyle interventions in overweight and obese participants. The main questions it aims to answer are:
* effect on anthropometric measurements
* effect on lipid profile
* effect on weight-related quality of life
* observe the differences between interventions The study participants were stratified into three groups: intervention, control-1, and control-2.
* Intervention group: They were given a calorie-restricted diet and exercise plan by a dietician or physiotherapist at their first visit, and were followed up by telephone calls at weeks 2, 4, 6, 8 and 10 over 12 weeks.
* Control-1 group: During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
* Control-2 group: The participants were not provided with any programme, and the importance of weight loss was emphasised by the family physicians. Dietary and physical activity advice was given according to the recommendations in the Turkish Endocrine and Metabolism Association 2019 Obesity Diagnosis and Treatment Guide, and was followed up with phone calls at weeks 2, 4, 6, 8 and 10 over a 12-weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duygu Ayhan Baser
Last refreshed: 4 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06321809.